LEXARIA BIOSCIENCE CORP. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
LEXARIA BIOSCIENCE CORP. (LEXX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $2.98 per share for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2021-11-30 was $9.60, a 25.58% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2020-11-30 was $12.90, a 56.29% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2019-11-30 was $29.51.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $2.98, a 68.96% decline from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $9.60, a 10.78% decline from fiscal 2021.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2021 was $10.76, a 63.54% decline from fiscal 2020.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2020 was $29.51, a 4371.21% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-05-31 | $2.98 10-Q · filed 2026-07-13 | ||||
| 2025-08-31 | $7.78 10-Q · filed 2026-07-13 | ||||
| 2023-08-31 | $2.98 10-K · filed 2023-11-20 | ||||
| 2022-08-31 | $9.60 10-K · filed 2023-11-20 | ||||
| 2022-05-31 | $9.60 10-Q · filed 2022-07-14 | ||||
| 2022-02-28 | $9.60 10-Q · filed 2022-04-11 | ||||
| 2021-11-30 | $9.60 10-Q · filed 2022-01-14 | ||||
| 2021-08-31 | $10.76 10-K · filed 2022-11-28 | ||||
| 2021-05-31 | $10.85 10-Q · filed 2021-07-15 | ||||
| 2021-02-28 | $12.90 10-Q · filed 2021-04-14 | ||||
| 2020-11-30 | $12.90 10-Q · filed 2021-01-14 | ||||
| 2020-08-31 | $29.51 10-K · filed 2021-11-29 | $0.98 10-K · filed 2020-10-15 | |||
| 2020-05-31 | $0.98 10-Q · filed 2020-06-29 | ||||
| 2020-02-29 | $0.09 10-Q · filed 2020-04-03 | ||||
| 2019-11-30 | $29.51 10-Q · filed 2021-01-14 | ||||
| 2019-08-31 | $0.66 10-K · filed 2020-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |